INDEMNITY AGREEMENTIndemnity Agreement • November 15th, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Delaware
This Indemnity Agreement, dated as of [•], 2018 is made by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and [•], a director, officer or key employee of the Company or one of the Company’s subsidiaries or other service provider who satisfies the definition of Indemnifiable Person set forth below (“Indemnitee”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 15th, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of March 16, 2021 by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 15th, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is dated as of June 22, 2023, by and among Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
AGREEMENT AND PLAN OF MERGER by and among: AEGLEA BIOTHERAPEUTICS, INC., a Delaware corporation; ASPEN MERGER SUB I, INC., a Delaware corporation; SEQUOIA MERGER SUB II, LLC, a Delaware limited liability company; and SPYRE THERAPEUTICS, INC., a...Agreement and Plan of Merger • November 15th, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of June 22, 2023, by and among AEGLEA BIOTHERAPEUTICS, INC., a Delaware corporation (“Parent”), ASPEN MERGER SUB I, INC., a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), SEQUOIA MERGER SUB II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and together with First Merger Sub, “Merger Subs”), and SPYRE THERAPEUTICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
June 22, 2023 Cameron Turtle Re: Offer of Employment Dear Cameron:Aeglea BioTherapeutics, Inc. • November 15th, 2023 • Pharmaceutical preparations
On behalf of Aeglea BioTherapeutics, Inc. (the “Company”), I am very pleased to offer you a position as Chief Operating Officer of the Company (the “Role”) pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated by your signature below.
ASSET PURCHASE AGREEMENT dated as of July 27, 2023 by and between AEGLEA BIOTHERAPEUTICS, INC. and IMMEDICA PHARMA ABAsset Purchase Agreement • November 15th, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • New York
AEGLEA BIOTHERAPEUTICS, INC. STOCK RESTRICTION AGREEMENTStock Restriction Agreement • November 15th, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Delaware
This Stock Restriction Agreement (this “Agreement”) is made and entered into as of March 10, 2015 (the “Effective Date”) by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and (“Stockholder”).
SEPARATION AND CONSULTING AGREEMENT AND GENERAL RELEASE OF CLAIMSSeparation and Consulting Agreement • November 15th, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas
This SEPARATION AND CONSULTING AGREEMENT AND GENERAL RELEASE OF CLAIMS (this “Agreement”) is entered into by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and Jonathan Alspaugh (“Executive”). Executive and the Company are each referred to herein as a “Party” and collectively as the “Parties.”
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 15th, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 22, 2023, by and among AEGLEA BIOTHERAPEUTICS, INC., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
SEVERANCE AGREEMENTSeverance Agreement • November 15th, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas
This Severance Agreement (the “Agreement”) is entered into as of April __, 2018 (the “Effective Date”) by and between __________________ (the “Executive”) and Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”).
